News Releases

Date Title  
Toggle Summary Dermira to Report Fourth Quarter 2018 Results and Host Conference Call on Tuesday, February 26, 2019
MENLO PARK, Calif. , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, will report
Toggle Summary Almirall and Dermira Enter into Option and License Agreement for European Rights to Lebrikizumab
-  Almirall acquires option to license rights to develop and commercialize lebrikizumab for atopic dermatitis in Europe -  Dermira to receive an option fee of $30 million -  Lebrikizumab is an investigational anti-IL-13 monoclonal antibody currently in Phase 2b development with topline data
Toggle Summary Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif. , Dec. 11, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today
Toggle Summary Dermira Enters into Credit Facility with Athyrium Capital Management
Facility provides additional financial flexibility in connection with ongoing QBREXZA launch and lebrikizumab program MENLO PARK, Calif. , Dec. 04, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by
Toggle Summary Dermira to Present at Evercore ISI HealthCONx Conference
MENLO PARK, Calif. , Nov. 19, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today
Toggle Summary Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today
Toggle Summary Dermira Reports Third Quarter 2018 Financial Results
Conference call today at 1:30 p.m. PT / 4:30 p.m. ET MENLO PARK, Calif. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of
Toggle Summary Dermira to Report Third Quarter 2018 Results and Host Conference Call on Wednesday, November 7, 2018
MENLO PARK, Calif. , Oct. 31, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, will report
Toggle Summary Dermira Completes Patient Enrollment in Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
Topline efficacy and safety results anticipated by early April 2019     MENLO PARK, Calif. , Oct. 23, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the
Toggle Summary Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif. , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today
Toggle Summary Dermira and Christian Siriano Collaborate to Inspire People Living with Excessive Underarm Sweating to Feel Confident in Their Own Skin
Mr. Siriano invites the millions of people living with hyperhidrosis in the U.S. to share their ‘sweat stories’ MENLO PARK, Calif., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by
Toggle Summary Dermira’s QBREXZA™ (glycopyrronium) Cloth Is Now Available in Pharmacies Nationwide for the Treatment of Primary Axillary Hyperhidrosis
QBREXZA is now available in retail and community pharmacies across the United States QBREXZA is the first and only FDA-approved, once-daily, topical prescription treatment indicated for people 9 years of age and older with primary axillary hyperhidrosis, also known as excessive underarm sweating
Toggle Summary Dermira to Present at Cantor 2018 Global Healthcare Conference
MENLO PARK, Calif. , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today
Toggle Summary Dermira Presents New Pediatric Efficacy and Safety Data for Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis at the European Academy of Dermatology and Venereology Congress
Primary axillary hyperhidrosis is a medical condition that can occur in the pediatric population and is largely undertreated and under-diagnosed Post-hoc analysis of ARIDO long-term safety study demonstrated reduced sweat production, and improved disease severity and quality of life, relative to
Toggle Summary Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif. , Sept. 10, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today
Toggle Summary Dermira Provides Launch Readiness Update for QBREXZA™ (glycopyrronium) Cloth for Primary Axillary Hyperhidrosis
Early commercial payer coverage for the therapy includes Express Scripts, Inc. and OptumRx Company announces DermiraConnect, a new patient access program that will provide patients broad access to QBREXZA Therapy is expected to be available in pharmacies nationwide beginning October 1, 2018 MENLO
Toggle Summary Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today
Toggle Summary Dermira Reports Second Quarter 2018 Financial Results and Provides Corporate Update 
- QBREXZA™ (glycopyrronium) cloth for the treatment of primary axillary hyperhidrosis approved in June 2018 - QBREXZA expected to be available nationwide in pharmacies beginning in October 2018 - Lebrikizumab Phase 2b enrollment expected to be completed by end of 2018 MENLO PARK, Calif. , Aug.
Toggle Summary Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif. , July 10, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced
Toggle Summary Dermira Receives FDA Approval for Qbrexza™ (glycopyrronium) Cloth to Treat Primary Axillary Hyperhidrosis
Qbrexza is the first FDA -approved, once-daily, topical prescription treatment indicated for people with primary axillary hyperhidrosis, also known as excessive underarm sweating The chronic, medical skin condition is estimated to affect nearly 10 million people in the U.S.
Toggle Summary Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif. , June 08, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced
Toggle Summary Dermira to Present at Jefferies 2018 Global Healthcare Conference
MENLO PARK, Calif. , May 30, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced
Toggle Summary Dermira to Host Analyst & Investor Day on May 24, 2018
MENLO PARK, Calif. , May 14, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, will host a live
Toggle Summary Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif. , May 08, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced
Toggle Summary Dermira Reports First Quarter 2018 Financial Results and Provides Corporate Update
FDA decision on glycopyrronium tosylate New Drug Application expected by June 30, 2018 Lebrikizumab Phase 2b study enrolling patients, data expected in first half of 2019 MENLO PARK, Calif. , May 03, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to
Toggle Summary Dermira and Cameran Eubanks Team Up to Raise Awareness of Excessive Sweating for the 15 Million People Living with the Condition in the U.S.
MENLO PARK, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- Reality television personality Cameran Eubanks and Dermira, Inc. (NASDAQ:DERM) announced today that they are collaborating on a new educational campaign aimed at raising awareness of hyperhidrosis, a medical condition that results in sweating
Toggle Summary Dermira to Present at Deutsche Bank 43rd Annual Healthcare Conference
MENLO PARK, Calif. , May 01, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced
Toggle Summary Christopher Horan Joins Dermira as Chief Technical Operations Officer
Previously served as Senior Vice President, Global Product and Supply Chain Management at Genentech, Inc. ( Roche ) Brings more than 25 years of biopharma operations experience to Dermira     MENLO PARK, Calif. , April 19, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc.
Toggle Summary Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif. , April 11, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today
Toggle Summary Dermira to Present at 17th Annual Needham Healthcare Conference
MENLO PARK, Calif. , March 20, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today
Toggle Summary Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif. , March 08, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today
Toggle Summary Dermira to Present at Cowen & Company 38th Annual Healthcare Conference
MENLO PARK, Calif. , March 08, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today
Toggle Summary Dermira’s Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpoints
Company expects to discontinue the program Conference call and webcast today at 8:30 a.m. ET / 5:30 a.m. PT         MENLO PARK, Calif. , March 05, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to delivering new therapies to patients living with chronic
Toggle Summary Dermira Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
Olumacostat glasaretil topline Phase 3 data expected Q1 2018 FDA decision on glycopyrronium tosylate New Drug Application expected by June 30, 2018 Lebrikizumab Phase 2b study enrolling patients and data expected H1 2019 MENLO PARK, Calif. , Feb. 22, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc.
Toggle Summary New Data in Pediatric Patients with Axillary Hyperhidrosis Presented During Late-Breaking Research Forum at the 76th Annual Meeting of the American Academy of Dermatology
SAN DIEGO , Feb. 17, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today presented new
Toggle Summary Dermira Showcases Commitment to Hyperhidrosis Education and Treatment at Leading Dermatology Conference
MENLO PARK, Calif. , Feb. 12, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced
Toggle Summary Dermira to Present at Leerink Partners 7th Annual Global Healthcare Conference
MENLO PARK, Calif. , Feb. 09, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced
Toggle Summary Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif. , Feb. 08, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced
Toggle Summary Dermira Initiates Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
Study expected to enroll approximately 275 patients Topline results expected in the first half of 2019 TREBLE Phase 2 proof-of-concept results published in the Journal of the American Academy of Dermatology MENLO PARK, Calif. , Jan. 31, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc.
Toggle Summary Dermira to Present at Upcoming Investor Conferences in November
MENLO PARK, Calif. , Nov. 09, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced
Toggle Summary Dermira Reports Third Quarter 2017 Financial Results and Announces that FDA Accepts New Drug Application for Glycopyrronium Tosylate for the Treatment of Patients with Primary Axillary Hyperhidrosis
- FDA decision on New Drug Application expected by June 30, 2018 - Licensed exclusive, worldwide rights to lebrikizumab from Roche - Completed patient enrollment in two Phase 3 trials for the treatment of acne vulgaris - Agreed to end collaboration agreement with UCB for CIMZIA MENLO PARK, Calif.
Toggle Summary Dermira and UCB Agree to End Collaboration Agreement for CIMZIA
Dermira to transition development and commercialization responsibility for CIMZIA ® (certolizumab pegol) in psoriasis back to UCB Decision reflects both companies’ strategic priorities UCB remains committed to bringing CIMZIA to psoriasis patients upon regulatory approval Dermira to hold conference
Toggle Summary Dermira Highlights New Long-Term Safety Data for Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis at Fall Clinical Dermatology Conference
- Daily treatment with glycopyrronium tosylate in the Phase 3, open-label ARIDO trial was generally well-tolerated during 44 weeks of treatment - Efficacy assessment suggests sweat reduction levels were maintained in patients treated with glycopyrronium tosylate during the extended study MENLO
Toggle Summary Dermira Completes Patient Enrollment in Two Phase 3 Pivotal Trials of Olumacostat Glasaretil for the Treatment of Acne Vulgaris
- Phase 3 pivotal trials enrolled a total of 1,503 patients - Topline efficacy and safety results expected in first quarter of 2018 MENLO PARK, Calif. , Oct. 05, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical
Toggle Summary Dermira to Present at Cantor Fitzgerald Global Healthcare Conference
MENLO PARK, Calif. , Sept. 20, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today
Toggle Summary Dermira Announces Early Termination of the Hart-Scott-Rodino Waiting Period for License to Lebrikizumab
MENLO PARK, Calif. , Sept. 14, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today
Toggle Summary New CIMZIA® (certolizumab pegol) Findings Presented at European Academy of Dermatology and Venereology (EADV) Congress
Presentations included the first 48-week data from the CIMPASI-1 and CIMPASI-2 psoriasis trials, and re-randomized data through 48 weeks from the CIMPACT psoriasis trial 1,2 Treatment with CIMZIA was associated with significant and clinically meaningful improvements in quality of life and work
Toggle Summary Dermira Presents New Data Showing Impact of Primary Axillary Hyperhidrosis on Patients
People suffering from primary axillary hyperhidrosis (excessive underarm sweating beyond what is needed to maintain normal body temperature) report that the condition has a significant impact on their daily lives, often resulting in avoidance of social interactions and taking additional measures to
Toggle Summary Dermira Presents New Data on Late-Stage Programs at Leading European Dermatology Congress
New findings from the glycopyrronium tosylate Phase 3 program highlight potential benefits of the investigational treatment and the impact of primary axillary hyperhidrosis on patients’ daily activities In collaboration with UCB, new 48-week data and quality of life findings from three clinical
Toggle Summary Dermira Enters into Agreement to License Exclusive, Worldwide Rights to Lebrikizumab
-  Dermira plans to develop and commercialize lebrikizumab, a monoclonal antibody targeting IL-13, for moderate-to-severe atopic dermatitis -  Initiation of a Phase 2b clinical study is expected in the first quarter of 2018 -  Management will host webcast and conference call today at
Toggle Summary Dermira Reports Second Quarter 2017 Financial Results and Provides Corporate Update
sBLA for CIMZIA® (certolizumab pegol) submitted to FDA Submission of NDA for glycopyrronium tosylate on schedule for second half of 2017 Guidance for Phase 3 olumacostat glasaretil topline results updated to first quarter of 2018 MENLO PARK, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc.
Toggle Summary UCB and Dermira Announce U.S. and EU Regulatory Submissions for CIMZIA® (certolizumab pegol) for the treatment of Moderate-to-Severe Chronic Plaque Psoriasis
  The regulatory submissions for this new indication seek to expand the use of CIMZIA for the treatment of patients with moderate-to-severe chronic plaque psoriasis Data from three positive Phase 3 studies support the regulatory submissions BRUSSELS, Belgium and MENLO PARK, Calif., July 25,
Toggle Summary Newly Published Nonclinical Data Highlight the Role of Olumacostat Glasaretil in Sebum Inhibition
MENLO PARK, Calif. , June 26, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced
Toggle Summary Dermira Announces Appointment of Ian Clements as Vice President, Investor Relations
MENLO PARK, Calif. , June 06, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, announced today
Toggle Summary Dermira to Present at Jefferies 2017 Global Healthcare Conference
MENLO PARK, Calif. , May 30, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced
Toggle Summary Dermira Announces Closing of 3.00% Convertible Senior Notes Offering
MENLO PARK, Calif. , May 16, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) announced today the closing of its previously announced offering of 3.00% Convertible Senior Notes due 2022 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the
Toggle Summary Dermira Prices Offering of $250 Million of 3.00% Convertible Senior Notes
MENLO PARK, Calif. , May 10, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) announced today the pricing of its offering of $250,000,000 aggregate principal amount of 3.00% Convertible Senior Notes due 2022 (the “notes”) in a private offering to qualified institutional buyers pursuant to the
Toggle Summary Dermira Announces Proposed Offering of $250 Million of Convertible Senior Notes
MENLO PARK, Calif. , May 09, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) announced today that it intends to offer, subject to market conditions and other factors, $250,000,000 aggregate principal amount of Convertible Senior Notes due 2022 (the “notes”) in a private offering to qualified
Toggle Summary Dermira Reports First Quarter 2017 Financial Results and Provides Corporate Update 
-Submissions for CIMZIA ® (certolizumab pegol) and glycopyrronium tosylate remain on schedule for later this year MENLO PARK, Calif. , May 08, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by
Toggle Summary Dermira to Present at Needham 16th Annual Healthcare Conference
MENLO PARK, Calif. , March 28, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today
Toggle Summary Dermira Presents New Data Highlighting Patient Outcomes in Axillary Hyperhidrosis at Maui Derm Meeting
Proprietary Axillary Sweating Daily Diary patient-reported outcome instrument developed with feedback from FDA MENLO PARK, Calif. , March 21, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by
Toggle Summary Dermira to Highlight Data for Three Clinical Programs at Annual Maui Derm Meeting
New data for the Axillary Sweating Daily Diary patient-reported outcome instrument from the glycopyrronium tosylate Phase 2 trial in primary axillary hyperhidrosis to be highlighted Additional data from the CIMPACT Phase 3 trial of CIMZIA® (certolizumab pegol) in patients with moderate-to-severe
Toggle Summary Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
MENLO PARK, Calif. , March 07, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today
Toggle Summary New CIMZIA® (certolizumab pegol) data in moderate-to-severe plaque psoriasis and psoriatic arthritis presented at American Academy of Dermatology 2017 Annual Meeting
Late-breaking, investigational 16-week data presented from the CIMPASI-1 and CIMPASI-2 trials showing CIMZIA demonstrated statistically and clinically significant improvements for patients with moderate-to-severe chronic plaque psoriasis Four-year data from the CIMZIA RAPID-PSA study showing
Toggle Summary Dermira Presents New Data in Primary Axillary Hyperhidrosis and Acne at American Academy of Dermatology 2017 Annual Meeting
Data from glycopyrronium tosylate Phase 3 program and olumacostat glasaretil Phase 2 trial show patients experienced early and sustained clinical effects with each treatment ORLANDO, Fla. , March 03, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to
Toggle Summary Dermira to Present at Cowen and Company 37th Annual Health Care Conference
MENLO PARK, Calif. , March 02, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today
Toggle Summary Dermira Prices $168.5 Million Public Offering of Common Stock
MENLO PARK, Calif. , March 01, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today
Toggle Summary Dermira Announces Proposed Public Offering of Common Stock
MENLO PARK, Calif. , Feb. 28, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced
Toggle Summary Dermira Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
-- Planned submission of NDA for glycopyrronium tosylate (formerly DRM04) in 2H17 on schedule after pre-NDA meeting with FDA -- -- Management to host webcast and conference call today 4:30 p.m. ET / 1:30 p.m. PT -- MENLO PARK, Calif. , Feb. 28, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc.
Toggle Summary Dermira Data from DRM04 and Olumacostat Glasaretil Clinical Programs to Be Presented at American Academy of Dermatology Annual Meeting
MENLO PARK, Calif. , Feb. 27, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that data from
Toggle Summary Dermira to Report Fourth Quarter and Full Year 2016 Financial Results
Management to Host Webcast and Conference Call on February 28, 2017 at 4:30 p.m. ET MENLO PARK, Calif. , Feb. 22, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to
Toggle Summary Dermira to Present at Leerink Partners 6th Annual Global Healthcare Conference
MENLO PARK, Calif., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. DERM , a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it will present at
Toggle Summary Final CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Primary Efficacy Endpoint in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
CIMPACT results confirm data from two previously reported Phase 3 CIMZIA trials Submission of marketing applications to regulatory authorities expected in third quarter of 2017 BRUSSELS, Belgium and MENLO PARK, Calif. , Jan. 19, 2017 (GLOBE NEWSWIRE) -- UCB (Euronext:UCB) and Dermira, Inc.
Toggle Summary Dermira Provides Corporate Update
Treatment period for DRM04 ARIDO trial completed Phase 3 acne clinical program for olumacostat glasaretil initiated Topline data for third and final CIMZIA® (certolizumab pegol) Phase 3 trial expected first quarter of 2017 Chief Commercial Officer appointed MENLO PARK, Calif. , Jan.
Toggle Summary Lori Lyons-Williams Joins Dermira as Chief Commercial Officer
Previously served at Allergan as a Vice President for Sales & Marketing, member of Operational Leadership Team Worked on several leading dermatology brands including ACZONE® and BOTOX® during 15-year career at Allergan MENLO PARK, Calif. , Jan. 05, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc.
Toggle Summary Dermira Elects Emmanuel Caeymaex to Board of Directors
Currently Executive Vice President, Immunology Patient Value Unit Head at UCB S.A. MENLO PARK, Calif. , Jan. 04, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve
Toggle Summary Dermira Initiates Phase 3 Clinical Program in Acne
First patients dosed in Phase 3 program evaluating olumacostat glasaretil, a novel topical molecule, in patients with acne vulgaris Two Phase 3 trials expected to enroll a total of 1,400 patients Topline results expected in the first half of 2018 MENLO PARK, Calif. , Jan.
Toggle Summary Second CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
Topline results from CIMPASI-1, the second of three Phase 3 trials in psoriasis clinical development program Findings confirm CIMZIA results observed in earlier CIMPASI-2 trial Results from third and final Phase 3 trial expected 1Q17 BRUSSELS, Belgium and MENLO PARK, Calif. , Dec.
Toggle Summary Dermira to Present at Stifel 2016 Healthcare Conference
MENLO PARK, Calif. , Nov. 09, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it will
Toggle Summary Dermira Reports Third Quarter 2016 Financial Results and Provides Corporate Update
-  Topline results for the first of three Phase 3 trials for CIMZIA ® reported -  DRM04 Phase 3 and DRM01 Phase 2b data presented at dermatology conferences -  Acquired option to license rights to early-stage programs from Takeda -  Licensed DRM04 for hyperhidrosis to Maruho in Japan MENLO PARK,
Toggle Summary Dermira Presents Data from DRM01 Phase 2b Clinical Program at Annual Meeting for Dermatologists
MENLO PARK, Calif. , Oct. 21, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, presented data from its DRM01
Toggle Summary Dermira to Present Data from DRM01 and DRM04 Clinical Programs at Fall Clinical Dermatology Conference
MENLO PARK, Calif. , Oct. 13, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that data from
Toggle Summary CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
Topline results from the first of three Phase 3 trials in psoriasis clinical development program BRUSSELS, Belgium and MENLO PARK, Calif. , Oct. 03, 2016 (GLOBE NEWSWIRE) -- UCB (Euronext:UCB) and Dermira, Inc. (NASDAQ:DERM) today announced topline results from CIMPASI-2, a Phase 3, multi-center,
Toggle Summary Dermira Presents Data from DRM04 Phase 3 Clinical Program in Late-Breaking News Session at European Academy of Dermatology and Venereology Congress
MENLO PARK, Calif. , Oct. 01, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today presented data, including
Toggle Summary Dermira to Present Data from DRM04 Phase 3 Clinical Trials at Late-Breaking News Session at European Academy of Dermatology and Venereology Congress
MENLO PARK, Calif. , Sept. 28, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that data from
Toggle Summary Dermira Licenses DRM04 to Maruho for Hyperhidrosis in Japan
Terms include $25 million upfront license payment to Dermira Maruho to fund all development and commercial costs for DRM04 in Japan MENLO PARK, Calif. , Sept. 20, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and
Toggle Summary Dermira Acquires Option to License Exclusive Rights for up to Three Early-Stage Programs from Takeda
MENLO PARK, Calif. , Sept. 12, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it has
Toggle Summary Dermira Reports Second Quarter 2016 Financial Results and Provides Corporate Update
Reported Topline Results for Two Late-Stage Clinical Programs Raised Approximately $136 Million in Net Proceeds from Follow-on Public Offering Updates Guidance for Topline Phase 3 CIMZIA® (certolizumab pegol) Clinical Program Results MENLO PARK, Calif. , Aug.
Toggle Summary Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
MENLO PARK, Calif. , June 13, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it has
Toggle Summary Dermira Prices $126 Million Public Offering of Common Stock
MENLO PARK, Calif. , June 08, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced the pricing of
Toggle Summary Dermira Announces Proposed Public Offering of Common Stock
MENLO PARK, Calif. , June 07, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it intends
Toggle Summary Dermira Announces Positive Topline Results from Two Pivotal Phase 3 Clinical Trials for DRM04 in Patients with Primary Axillary Hyperhidrosis
Management to Host Webcast and Conference Call Today at 1:30 p.m. PT / 4:30 p.m. ET MENLO PARK, Calif. , June 01, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to
Toggle Summary Dermira to Present Preclinical Data from DRM01 Acne Program at the Society for Investigative Dermatology 75th Annual Meeting
MENLO PARK, Calif. , May 11, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that preclinical
Toggle Summary Dermira Reports First Quarter 2016 Financial Results and Provides Corporate Update
- Positive Topline Results for DRM01 Phase 2b Acne Trial Reported; Phase 3 Program Planning Underway - Announcement of Topline Results for DRM04 Phase 3 Hyperhidrosis Pivotal Trials Expected in Second Quarter of 2016 MENLO PARK, Calif. , May 10, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc.
Toggle Summary Dermira Announces Positive Topline Phase 2b Clinical Trial Results for DRM01 in Patients with Facial Acne Vulgaris
- Safety and Efficacy Data Confirm Results from Previous Phase 2a Trial - DRM01 Phase 3 Clinical Program Planning Underway - Management to Host Webcast and Conference Call Today at 5:30 a.m. PT / 8:30 a.m. ET MENLO PARK, Calif. , May 10, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc.
Toggle Summary Dermira to Present at 15th Annual Needham Healthcare Conference
MENLO PARK, Calif. , April 05, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced participation
Toggle Summary Dermira’s Co-founder and Chief Medical Officer, Eugene A. Bauer, M.D., Receives Presidential Citation from the American Academy of Dermatology
MENLO PARK, Calif. , March 14, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that Eugene A.
Toggle Summary Dermira Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
Management to Host Webcast and Conference Call Today at 5:30 a.m. PT / 8:30 a.m. ET MENLO PARK, Calif. , March 03, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to
Toggle Summary Dermira to Report Fourth Quarter and Full Year 2015 Financial Results
Management to Host Webcast and Conference Call on March 3, 2016 at 8:30 a.m. ET MENLO PARK, Calif. , March 01, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve
Toggle Summary Dermira to Present at Cowen and Company 36th Annual Health Care Conference
MENLO PARK, Calif. , March 01, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it will
Toggle Summary Dermira Completes Patient Enrollment for DRM04 Phase 3 Pivotal Trials in Primary Axillary Hyperhidrosis
Topline Results for Phase 3 ATMOS-1 and ATMOS-2 Clinical Trials Expected in 2Q 2016 MENLO PARK, Calif. , Feb. 29, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to
Toggle Summary Dermira to Present at the Leerink Partners 5th Annual Global Healthcare Conference
MENLO PARK, Calif. , Feb. 04, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it will
Toggle Summary Dermira Completes Patient Enrollment for Third CIMZIA® (certolizumab pegol) Phase 3 Clinical Trial in Psoriasis Program and Updates Guidance for Release of Topline Data
Enrollment for All Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Plaque Psoriasis Completed Dermira Plans to Announce Topline Data for Phase 3 Trials by End of First Quarter 2017   MENLO PARK, Calif. , Jan. 08, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc.
Toggle Summary Dermira Provides DRM01 and DRM04 Development Program Updates
Enrollment Completed in DRM01 Phase 2b Acne Trial; Topline Data Expected in 2Q16 Topline Data for DRM04 Phase 3 Hyperhidrosis Program Expected Mid-2016 MENLO PARK, Calif. , Jan. 07, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying,
Toggle Summary Dermira Added to NASDAQ Biotechnology Index
MENLO PARK, Calif. , Dec. 15, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced that the company has been selected for addition to the NASDAQ
Toggle Summary Dermira Completes Patient Enrollment for Second CIMZIA(R) (certolizumab pegol) Phase 3 Clinical Trial in Psoriasis Program
Enrollment Continues for Third and Final CIMZIA Phase 3 Trial in Patients With Moderate-to-Severe Plaque Psoriasis MENLO PARK, Calif. , Nov. 19, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to
Toggle Summary Dermira Reports Third Quarter 2015 Financial Results and Provides Corporate Update
Continued Progress for Three Late-Stage Development Programs MENLO PARK, Calif. , Nov. 10, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today reported
Toggle Summary Dermira Completes Patient Enrollment for First CIMZIA(R) (Certolizumab Pegol) Phase 3 Clinical Trial in Psoriasis Program
Patient Enrollment Continues for Two Additional CIMZIA Phase 3 Trials in Patients With Moderate-to-Severe Psoriasis MENLO PARK, Calif. , Oct. 12, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to
Toggle Summary Dermira Presents Data From DRM01 Phase 2a Trial at European Academy of Dermatology and Venereology
Includes New Data Regarding Effects Observed at Week 4 MENLO PARK, Calif. , Oct. 7, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced the
Toggle Summary Dermira Elects Kathleen Sebelius to Board of Directors
MENLO PARK, Calif. , Sept. 30, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced the election of Kathleen Sebelius , the 21 st U.S.
Toggle Summary Dermira to Present Data for DRM01 Acne Program at EADV Congress 2015
Additional Analyses of Phase 2a Study to Be Presented on October 7, 2015 MENLO PARK, Calif. , Sept. 29, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today
Toggle Summary Skin Disposition Study Results for Dermira's DRM01 Program in Acne Presented at International Dermatology Meeting
Animal Data Demonstrate Accumulation of DRM01 in Sebaceous Glands Following Topical Administration MENLO PARK, Calif. , Sept. 10, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists
Toggle Summary Dermira to Present Data for DRM01 Acne Program at 45th Annual ESDR Meeting
Results of Skin Disposition Study to be Presented on September 10, 2015 MENLO PARK, Calif. , Sept. 3, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today
Toggle Summary Dermira Reports Second Quarter 2015 Financial Results and Provides Corporate Update
Two Product Candidates Now in Phase 3 Development Approximately $104 Million in Net Proceeds From Recent Follow-on Public Offering MENLO PARK, Calif. , Aug. 13, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and
Toggle Summary Dermira Announces Closing of Follow-on Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
MENLO PARK, Calif. , Aug. 11, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced that it has closed its previously announced follow-on public
Toggle Summary Dermira Prices Follow-On Public Offering of Common Stock
MENLO PARK, Calif. , Aug. 5, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced the pricing of its follow-on public offering of 4,500,000 shares
Toggle Summary Dermira Commences Follow-on Public Offering of Common Stock
MENLO PARK, Calif. , Aug. 4, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced that it has commenced a follow-on public offering of 3,750,000
Toggle Summary Dermira Doses First Patients in DRM04 Phase 3 Program in Axillary Hyperhidrosis
Two Identical Studies to Enroll a Combined Total of 660 Patients Topline Phase 3 Data Expected in the Second Half of 2016 Represents Dermira's Second Product Candidate in Phase 3 Development Dermira Updates 2015 Financial Guidance MENLO PARK, Calif. , Aug. 3, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc.
Toggle Summary Dermira's Phase 2a DRM01 Acne Trial Data Presented at the World Congress of Dermatology Meeting
Primary Endpoints of Changes in Lesion Counts and Improvement in Investigator's Global Assessment (IGA) Score Met With Statistical Significance MENLO PARK, Calif. , June 9, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and
Toggle Summary Dermira Announces Poster Presentation on DRM01 in Acne at World Congress of Dermatology
Safety and Efficacy Results of Phase 2a Trial to be Displayed June 9-12, 2015 MENLO PARK, Calif. , June 2, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients,
Toggle Summary Dermira to Present at Jefferies 2015 Global Healthcare Conference
MENLO PARK, Calif. , May 28, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced that it will present at the Jefferies 2015 Global Healthcare
Toggle Summary Dermira Reports First Quarter 2015 Financial Results and Provides Corporate Update
Three Late-Stage Programs Continue to Progress MENLO PARK, Calif. , May 12, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today reported financial results
Toggle Summary Dermira Doses First Patient in DRM01 Phase 2b Acne Trial
Study to Enroll Approximately 400 Patients With Moderate-to-Severe Acne Vulgaris MENLO PARK, Calif. , April 9, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients,
Toggle Summary Dermira to Present at the 14th Annual Needham Healthcare Conference
MENLO PARK, Calif. , April 8, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced that it will present at the 14 th Annual Needham Healthcare
Toggle Summary Dermira Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate Update
DRM01 Phase 2b Trial in Acne to Start April 2015 Conference Call Today at 4:30 p.m. Eastern Time MENLO PARK, Calif. , March 25, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists
Toggle Summary Clinical Data for Dermira's DRM01 Acne Program Presented at Dermatology Meeting
Phase 2a Trial Met Primary Endpoints With Statistical Significance MENLO PARK, Calif. , March 23, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today
Toggle Summary Dermira to Report Fourth Quarter and Full Year 2014 Financial Results
Management to Host Webcast and Conference Call on March 25, 2015 at 4:30 p.m. ET MENLO PARK, Calif. , March 18, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated dermatology products to dermatologists and
Toggle Summary Dermira Announces Late-Breaking Oral Presentation on DRM01 in Acne at 2015 AAD Annual Meeting
Positive Results of Phase 2a Trial to be Presented on March 20, 2015 MENLO PARK, Calif. , March 12, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today
Toggle Summary Dermira Announces Positive Phase 2b Results for DRM04 in Patients With Hyperhidrosis
Phase 3 Program Expected to Start in Second Half of 2015 MENLO PARK, Calif. , Feb. 5, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced positive
Toggle Summary Dermira to Present at the 2015 Leerink Global Healthcare Conference
MENLO PARK, Calif. , Jan. 29, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced that it will present at the 2015 Leerink Global Healthcare
Toggle Summary Dermira and UCB Announce Start of Phase 3 Program for CIMZIA(R) (certolizumab pegol) in Psoriasis
Phase 3 program aims to address patient need for alternative treatment options in moderate-to-severe psoriasis   Program includes the first Phase 3 study in psoriasis comparing two anti-TNFs   Based on current enrollment projections, top-line data from these studies are expected in 2017 MENLO PARK,
Toggle Summary Dermira Added to Russell 2000(R) Index
MENLO PARK, Calif. , Dec. 22, 2014 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients, today announced that the company was added to the Russell
Toggle Summary Dermira Reports Third Quarter 2014 Financial Results and Provides Corporate Update
REDWOOD CITY, Calif. , Nov. 12, 2014 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients, today reported financial results for the quarter ended
Toggle Summary Dermira Prices Initial Public Offering
REDWOOD CITY, Calif. , Oct. 2, 2014 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients, today announced the pricing of its initial public offering
Toggle Summary Dermira Completes $51 Million Financing and Expands Management Team and Board of Directors
REDWOOD CITY, CA – August 19, 2014 – Dermira, a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients, today announced that it has completed a $51 million Series C financing.
Toggle Summary UCB and Dermira enter into strategic collaboration in dermatology to broaden patient access to Cimzia® (certolizumab pegol)
UCB and Dermira enter into strategic collaboration in dermatology to broaden patient access to Cimzia ® (certolizumab pegol) Dermira obtains exclusive rights to develop Cimzia ® in psoriasis in the US, Canada and the European Union Driven by positive Phase 2 results with Cimzia ® in psoriasis and
Toggle Summary Dermira Announces Development and Corporate Progress
Five Ongoing Phase 2 Clinical Trials Targeting Acne, Psoriasis, Atopic Dermatitis, Rosacea and Hyperhidrosis REDWOOD CITY, CA – Dermira, a development-stage biotechnology company focused on developing innovative medical dermatology products for dermatologists and their patients, announces the
Toggle Summary Dermira Raises $35M to Fund Innovation in Dermatology
Existing Investors Joined by Maruho, the Leading Dermatology Company in Japan REDWOOD CITY, CA – June 11, 2013 – Dermira, a development-stage biotechnology company focused on developing and commercializing innovative new therapies in dermatology, today announced that it has raised $35 million of
Toggle Summary A Win for Skin
Dermira aims $40M at clear target:  Acne BY RON LEUTY San Francisco Business Times Vol. 27, No. 28 February 1–7, 2013 Tom Wiggans and Gene Bauer are putting more skin in the game. The dynamic duo of dermatology drug companies — who led, built and sold Bay Area companies Peplin Inc.
Toggle Summary Dermira Announces a $42m Series A Financing to Fund Therapeutic Advances in Dermatology
October 20, 2011 – Dermira today announced a $42 million Series A financing to support the acquisition, development and commercialization of novel therapeutics in dermatology. The company was founded and seed financed in late 2010 by former members of the Peplin and Connetics leadership teams,